Table S4.12 Neisseria gonorrhoeae decreased susceptibility to ceftriaxone (MIC 0.06–0.125 mg/L), by jurisdiction, 2009–14
Jurisdiction
2009, % of all isolates (n)
2010, % of all isolates (n)
2011, % of all isolates (n)
2012, % of all isolates (n)
2013, % of all isolates (n)
2014, % of all isolates (n)
ACT
5.3 (2)
6.7 (2)
3.1 (2)
3.6 (2)
0.0 (0)
2.7 (2)
NSW
1.7 (16)
5.6 (74)
4.4 (58)
4.5 (76)
11.8 (183)
7.1 (119)
NT: total
0.2 (1)
0.2 (1)
0.4 (2)
0.0 (0)
–
–
NT: urban and rural
na
na
na
na
1.9 (2)
3.0 (3)
NT: remote
na
na
na
na
0.8 (2)
0.8 (1)
Qld
1.8 (10)
3.2 (26)
2.3 (18)
2.4 (17)
4.9 (33)
3.2 (21)
SA
5.3 (9)
11.6 (19)
0.7 (1)
0.7 (1)
1.9 (4)
1.0 (2)
Tas
0.0 (0)
0.0 (0)
0.0 (0)
0.0 (0)
24.4 (11)
0.0 (0)
Vic
2.2 (17)
5.7 (52)
5.3 (50)
8.4 (105)
11.8 (181)
6.6 (95)
WA: total
3.1 (9)
5.2 (17)
0.7 (3)
1.2 (6)
2.7 (13)
–
WA: urban and rural
na
na
na
na
na
3.6 (14)
WA: remote
na
na
na
na
na
0.9 (1)
Australia
2.0 (64)
4.8 (191)
3.2 (134)
4.4 (207)
8.8 (429)
5.4 (258)
– = total for state or territory separated into urban and rural, and remote; ACT = Australian Capital Territory; MIC = minimum inhibitory concentration; na = not available; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia
Note: An additional isolate from the Northern Territory had a MIC of 0.5 mg/L to ceftriaxone, the highest recorded in Australia (see paper in the New England Journal of Medicine).
Table S4.13 Percentage of Neisseria gonorrhoeae isolates with decreased susceptibility to ceftriaxone (MIC 0.06–0.125 mg/L), 2010–14
Ceftriaxone MIC (mg/L)
2010
2011
2012
2013
2014
0.06
4.6
3.2
4.1
8.2
4.8
0.125
0.1
0.1
0.3
0.6
0.6
MIC = minimum inhibitory concentration
Note: An additional isolate from the Northern Territory in 2013 had a MIC of 0.5 mg/L to ceftriaxone, the highest recorded in Australia (see paper in the New England Journal of Medicine).
